INMAZEB

ATOLTIVIMAB, MAFTIVIMAB, and ODESIVIMAB-EBGN · Regeneron Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for INMAZEB, covering 2021-09-29 to 2026-01-22. Get the full timeline:

Most recent: Clinical Trial Update: Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers [Phase 2]

See pricing